Recent evidence indicates that Aβ can misfold and aggregate into seeds that
structurally corrupt native proteins, mimicking a prion-like process. Several
studies using FAD animal models have demonstrated that intracerebral
infusion of brain extracts from APP-transgenic mice or AD patients induce
Aβ deposition and cerebral amyloid angiopathy. To carry out most of these
Aβ-seeding studies, APP-transgenic animal have been used. Nevertheless, it
remains to be elucidated whether Aβ deposition can be induced by Aβ-seeds
in a sporadic AD model that does not overexpress APP and produces wild
type human Aβ.
We used an innovative model to better understand the amyloidogenic events
that occur in sporadic AD. This hAβ-KI model, expresses wild-type human
Aβ under the control of the endogenous mouse APP gene. Aβ-seeds from
AD patients (stage C) from the AD Research Center (UCI) were
administered into 7-8-month-old hAβ-KI and as positive controls 3xTg-AD
mice were employed.
We demonstrated that amyloid seeds can stimulate Aβ aggregations in
3xTg-AD and hAβ-KI models. We found that Aβ aggregates occur earlier
in the 3xTg-AD vs hAβ-KI and that a longer term of treatment is necessary
to accelerate diffusible Aβ pathology in the hAβ-KI mice. Thereferoe, this
hAβ-KI model represents an important step towards the development of
next-generation animal models that will provide better predictive outcomes
for human patients.
Grants support: UCI MIND Pilot project (DBV), Ministry of Science
PID2019-108911RA-100 (DBV), U54 AG054349 (FML), Institute of
Health Carlos III PI18/01557 (AG) co-financed by FEDER funds (European
Union), NIH/NIA Grant P50 AG16573 (UCI-ADRC).